The authors were interested in the impact on clinical outcomes of the early use of neuraminidase inhibitors (NAIs) in hospitalised patients. They performed a retrospective cohort study of all adults hospitalised in a tertiary care hospital with confirmed influenza between 2009–2014. 699 patients were admitted with influenza during these five influenza seasons. 83.4% received NAI therapy but only 26.0% received the first dose within 6 hours of hospitalisation (early NAI). Patients with diabetes mellitus or who were pregnant were significantly more like to receive early NAI, as were those reporting fever or myalgia at presentation. Immunosuppressed patients were significantly less likely to receive early NAI. Early NAI was associated with a significantly shorter hospital length of stay (2.8 days vs. 3.9 days for those receiving NAI between 6–24 hours vs. 5.6 days for those who received NAI after 24 hours). No patients died in the early NAI group compared with 18 deaths in the 399 patients receiving NAI after 6 hours (4.5%) and four deaths in the 116 patients not receiving NAI (3.4%). Therefore early NAI therapy is associated with shorter length of stay in patients admitted with influenza.
Read more here